CN103570681A - Prepration method of esomeprazole key intermediate - Google Patents
Prepration method of esomeprazole key intermediate Download PDFInfo
- Publication number
- CN103570681A CN103570681A CN201210256556.8A CN201210256556A CN103570681A CN 103570681 A CN103570681 A CN 103570681A CN 201210256556 A CN201210256556 A CN 201210256556A CN 103570681 A CN103570681 A CN 103570681A
- Authority
- CN
- China
- Prior art keywords
- esomeprazole
- preparation
- key intermediate
- compound
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KOFBRZWVWJCLGM-UHFFFAOYSA-N COc1ccc2[nH]c(S)nc2c1 Chemical compound COc1ccc2[nH]c(S)nc2c1 KOFBRZWVWJCLGM-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1cnc(CSC(*c2c3)=Nc2ccc3OC)c(C)c1OC Chemical compound Cc1cnc(CSC(*c2c3)=Nc2ccc3OC)c(C)c1OC 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention provides a preparation method of esomeprazole key intermediate 5-methoxy-2-(4-methoxy-3, 5-dimethyl-2-pyridinyl)methyl thio-1H-benzoimidazole from 4-methoxy-3, 5-dimethyl-2-hydroxymethylpyridine. The preparation method helps to substantially shorten reaction period, improve yield, simplify reaction and post-processing operation, and is capable of efficiently preparing the esomeprazole key intermediate in large scale with low cost and high atom economy.
Description
Technical field
The present invention relates to a kind of preparation method of esomeprazole key intermediate.
Background technology
Esomeprazole, chemistry 5-methoxyl group-2-((S)-((4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl) sulfinyl)-1H-benzoglyoxaline by name.A kind of proton pump inhibitor, by suppressing the H of parietal cell
+/ K
+-ATP enzyme reduces gastric acid secretion, prevents the formation of hydrochloric acid in gastric juice.Clinical in eliminating pylorus, the treatment of gastro oesophageal reflux disease (GORD) (GERD)-erosive reflux esophagitis.The esophagitis patient who has cured prevents the long term maintenance treatment of recurrence.The symptom of gastro oesophageal reflux disease (GORD) (GERD) is controlled.With suitable antimicrobial therapy drug combination eradicate helicobacter pylori, healing is infected relevant duodenal ulcer to helicobacter pylorus, prevents the illnesss such as recurrent peptic ulcer relevant to helicobacter pylori.Esomeprazole can become Esomeprazole sodium through simple salify, or esomeprazole magnesium, is marketed drug.
The preparation of above-mentioned esomeprazole and one-tenth product salt thereof, all needs methyl sulfo--1H-benzoglyoxaline (compound IV) through key intermediate 5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl).Patent CN100374436C discloses a kind of by (4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl alcohol obtains 4-methoxyl group-3 through chloro-dehydroxylation reaction, 5-dimethyl-2-pyrmethyl chloride, under alkali exists, method with 2-sulfenyl-5-methoxyl group benzo imidazoles generation 5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl sulfo--1H-benzoglyoxaline.The method is long reaction time, and aftertreatment is more complicated, and subordinate phase operation is more complicated, and yield is low.
Summary of the invention
Technical problem to be solved by this invention has been to provide a kind of preparation method of new esomeprazole key intermediate, it is Reaction time shorten greatly, equal 0.5-2h of step reaction times 1., 2., operation is very simplified, products obtained therefrom HPLC purity > 98%.Products therefrom, according to known disclosed technology, through a simple step asymmetric oxidation reaction, just can obtain esomeprazole product.It can obviously improve productive rate and the quality of esomeprazole, shortens reaction time.
The preparation method of esomeprazole key intermediate disclosed by the invention comprises following steps:
1. in organic solvent, Compound I obtains intermediate II through bromo-dehydroxylation reagent react.
2. Compound I I and compound III obtain compound IV through electrophilic substitution reaction.
Wherein Compound I is: 4-methoxyl group-3,5-dimethyl-2-piconol
Wherein Compound I I is: 4-methoxyl group-3,5-dimethyl-2-bromo methyl cycloheptapyridine
Wherein compound III is: 5-methoxyl group-2-sulfydryl-1H-benzoglyoxaline
Wherein compound IV is: 5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl sulfo--1H-benzoglyoxaline
1. step adopts method and the condition of the conventional bromo-dehydroxylation reaction of this professional domain to carry out, and its optimal conditions is as follows:
The temperature of reaction is-20～60 ℃, preferably under room temperature, carries out; The time of reaction is as the criterion completely with detection reaction, is generally 0.1-24h, preferably 1.0-1.5h; Organic solvent in reaction is the conventional organic solvent of this area, comprises one or more in tetrahydrofuran (THF), methylene dichloride, toluene, DMF, acetone, pyridine, acetonitrile, preferably methylene dichloride; The mol ratio of the consumption of Compound I a and Compound I consumption is 1: 1.2 left and right, preferably 1: 1.2.This reacts bromo-dehydroxylation reagent used is phosphorus tribromide or perbrome-acetone, preferably phosphorus tribromide.
1. step reacts gained reaction solution, after the simple washing of alkali (sodium bicarbonate/potassium, sodium carbonate/potassium, sodium hydroxide/potassium) water liquid, directly carries out step reaction 2..
2. step adopts the method for the conventional electrophilic substitution reaction of this professional domain and condition to carry out, and its optimal conditions is as follows:
The temperature of reaction is-20～60 ℃, preferably under room temperature, carries out; The time of reaction is as the criterion is generally 0.1-24h completely with detection reaction, preferably 1.0-1.5h; Organic solvent in reaction is the conventional organic solvent of this area, comprises one or more in tetrahydrofuran (THF), methylene dichloride, toluene, DMF, acetone, pyridine, acetonitrile, preferably methylene dichloride; The mol ratio of the consumption of compound III and Compound I I consumption is 1: 1 left and right, preferably 1: 1.This reaction is at common solid acid binding agent: sodium bicarbonate, sodium carbonate, saleratus, salt of wormwood, sodium hydroxide, potassium hydroxide etc., or liquid acid binding agent: triethylamine, N, dinethylformamide etc., especially under the effect without any catalyzer or acid binding agent, the IV that obtains compound of atom economy.Gained reaction solution is adjusted PH=8-9 with alkaline solution, and organic phase adds one or both in low polar solvent sherwood oil, hexanaphthene to separating out a large amount of white solid products.
Accompanying drawing explanation:
Fig. 1: the HPLC spectrogram of embodiment of the present invention gained 5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl sulfo--1H-benzoglyoxaline.
Fig. 2: the mass spectrum of embodiment of the present invention gained 5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl sulfo--1H-benzoglyoxaline.
Fig. 3: the nucleus magnetic hydrogen spectrum figure of embodiment of the present invention gained 5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl sulfo--1H-benzoglyoxaline.
Embodiment
With embodiment, further illustrate the present invention below, but the present invention is not limited.
Embodiment 1:4-methoxyl group-3, the preparation of 5-dimethyl-2-picolyl bromine (Compound I I).
In 10L there-necked flask, add 800g (4.79mmol) Compound I, 6L methylene dichloride, is stirred to dissolve.Under normal temperature, drip 1555g (5.74mmol) Compound I a, drip and finish, room temperature reaction 1.0h, TLC point sample detects, and shows that reaction is complete, adds saturated Na
2cO
3solution extraction is washed 3 times (2L/ time), washes 2 times (2L/ time).Anhydrous sodium sulfate drying, suction filtration, filtrate for later use.
The preparation of embodiment 2:5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl sulfo--1H-benzoglyoxaline (compound IV)
In 10L there-necked flask, add embodiment 1 gained filtrate, add 2-sulfenyl-5-methoxyl group benzo imidazoles 862g (4.79mmol), mechanical stirring 1.5h, there are a large amount of solids to separate out, add three times (2L/ time) of saturated sodium carbonate solution washing, organic phase anhydrous sodium sulfate drying, be concentrated into 2L, add sherwood oil 6L.A large amount of white solids are separated out in stirring, suction filtration, and 45 ° of drying under reduced pressure of filter cake, to constant weight, obtain product 1526.2g, yield: 92.3%.(to drop into 4-methoxyl group-3, the step that 5-dimethyl-2-piconol calculates total recovery 1., 2.).
MS(+1)：330。
1HNMR：δ(ppm，CDC1
3)，8.12(s，H，N＝CH)，7.37(d，1H，Ar-H)，7.00(s，1H，Ar-H)，6.85(q，1H，Ar-H)，4.87(s，1H，-NH)，4.53(s，2H，S-CH
2)，3.82(s，3H，-OCH
3)，3.76(s，3H，-OCH
3)，2.26(s，3H，-CH
3)，2.25(s，3H，-CH
3)。
Claims (10)
1. one kind by 4-methoxyl group-3, and 5-dimethyl-2-piconol (I) is prepared the preparation method of esomeprazole key intermediate 5-methoxyl group-2-(4-methoxyl group-3,5-dimethyl-2-pyridyl) methyl sulfo--1H-benzoglyoxaline (IV)
Its preparation method comprises following step:
1. in organic solvent, Compound I obtains intermediate II through bromo-dehydroxylation reagent react.
2. Compound I I and compound III obtain compound IV through electrophilic substitution reaction.
2. the preparation method of esomeprazole key intermediate as claimed in claim 1, is characterized in that: step 1., step temperature of reaction is 2.-20～60 ℃.
3. the preparation method of esomeprazole key intermediate as claimed in claim 1, is characterized in that: step 1., the step reaction times is 2. 0.1～24h.
4. the preparation method of the crucial key intermediate of esomeprazole as claimed in claim 1, it is characterized in that: step 1., the organic solvent of step in be 2. one or more in tetrahydrofuran (THF), methylene dichloride, toluene, DMF, acetone, pyridine, acetonitrile.
5. the preparation method of esomeprazole key intermediate as claimed in claim 1, is characterized in that: step 1. in the consumption of Compound I a and the mol ratio of Compound I consumption be 1: 1.2 left and right; Step 2. in the consumption of compound III and the mol ratio of Compound I I consumption be 1: 1 left and right.
6. the preparation method of esomeprazole key intermediate as claimed in claim 1, is characterized in that: step 1. bromo-dehydroxylation reagent used is phosphorus tribromide or perbrome-acetone.
7. the preparation method of esomeprazole key intermediate as claimed in claim 1, is characterized in that: 1. step reacts gained reaction solution, after the simple washing of alkaline solution, directly carries out step reaction 2..
8. the preparation method of esomeprazole key intermediate as claimed in claim 1, it is characterized in that: step electrophilic substitution reaction is 2. at common solid acid binding agent: sodium bicarbonate, sodium carbonate, saleratus, salt of wormwood, sodium hydroxide, potassium hydroxide, or liquid acid binding agent: triethylamine, N, dinethylformamide, especially under the effect without any catalyzer or acid binding agent, the IV that obtains compound of atom economy.
9. the preparation method of the esomeprazole key intermediate as described in claim 1,8, is characterized in that: step 2. gained reaction solution is adjusted PH=8-9 with alkaline solution, and organic phase adds low polar solvent to separating out a large amount of white solid products.
10. as claimed in claim 9, low polar solvent is one or both in sherwood oil, hexanaphthene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210256556.8A CN103570681A (en) | 2012-07-24 | 2012-07-24 | Prepration method of esomeprazole key intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210256556.8A CN103570681A (en) | 2012-07-24 | 2012-07-24 | Prepration method of esomeprazole key intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103570681A true CN103570681A (en) | 2014-02-12 |
Family
ID=50043466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210256556.8A Pending CN103570681A (en) | 2012-07-24 | 2012-07-24 | Prepration method of esomeprazole key intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103570681A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106008464A (en) * | 2016-05-23 | 2016-10-12 | 江苏中邦制药有限公司 | Method for refining 5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridyl)methylthio-1H-benzimidazole crude product |
| CN110041307A (en) * | 2019-05-23 | 2019-07-23 | 江苏豪森药业集团有限公司 | The preparation method of esomeprazole sulfide intermediate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1705656A (en) * | 2002-10-18 | 2005-12-07 | 阿斯利康(瑞典)有限公司 | Method for the synthesis of a benzimidazole compound |
| US20070093523A1 (en) * | 2005-10-21 | 2007-04-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR modulators |
-
2012
- 2012-07-24 CN CN201210256556.8A patent/CN103570681A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1705656A (en) * | 2002-10-18 | 2005-12-07 | 阿斯利康(瑞典)有限公司 | Method for the synthesis of a benzimidazole compound |
| US20070093523A1 (en) * | 2005-10-21 | 2007-04-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR modulators |
Non-Patent Citations (1)
| Title |
|---|
| KARA M. JOSEPH ET AL.: "Synthesis of benzyl bromides with hexabromoacetone: an alternative path to drug intermediates", 《TETRAHEDRON LETTERS》, vol. 52, 31 October 2010 (2010-10-31), pages 13 - 16, XP027536636 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106008464A (en) * | 2016-05-23 | 2016-10-12 | 江苏中邦制药有限公司 | Method for refining 5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridyl)methylthio-1H-benzimidazole crude product |
| CN110041307A (en) * | 2019-05-23 | 2019-07-23 | 江苏豪森药业集团有限公司 | The preparation method of esomeprazole sulfide intermediate |
| CN110041307B (en) * | 2019-05-23 | 2021-12-17 | 江苏豪森药业集团有限公司 | Preparation method of esomeprazole thioether intermediate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102887886A (en) | Preparation method of pantoprazole sodium | |
| CN103232438B (en) | Pantoprazole sodium and preparation method thereof | |
| CN103709143A (en) | Preparation method of esomeprazole and magnesium salt thereof | |
| CN103073536B (en) | Preparation method of ilaprazole | |
| CN104402946A (en) | Invokana intermediate and preparation method thereof in amorphous form | |
| CN106117192A (en) | The synthetic method that a kind of En Gelie is clean | |
| CN101962379B (en) | Method for refining sulfonyl isoquinoline derivative | |
| CN102675285A (en) | Method for pure water phase preparation of rabeprazole sodium | |
| CN102351778A (en) | Preparation method of arbidol hydrochloride | |
| CN115772110A (en) | Method for preparing potassium ion competitive retarder non-surazan intermediate | |
| CN103570681A (en) | Prepration method of esomeprazole key intermediate | |
| CN105085484A (en) | Preparation method of vonoprazan fumarate | |
| CN104744449A (en) | Preparation method of canagliflozin hemihydrate and monocrystal thereof | |
| CN102702191B (en) | Synthesis method of vinpocetine | |
| CN104650039A (en) | Preparation method of ilaprazole | |
| CN104003981A (en) | Synthesis method of avanafil | |
| CN103804266B (en) | A kind of synthetic method of vildagliptin intermediate | |
| CN106518840A (en) | Synthetic method of 5-chloro-2-thiophenecarboxylic acid | |
| CN103664888B (en) | Preparation method of esomeprazole trihydrate | |
| CN109516938A (en) | A kind of Alfacalcidol derivative and preparation method thereof | |
| CN102952119B (en) | Sodium rabeprazole preparation method | |
| CN103059018A (en) | Praziquantel preparation process | |
| CN109574992B (en) | Preparation method of fasudil hydrochloride | |
| CN102702173B (en) | Method for preparing sulfur ether intermediates of proton pump inhibitor | |
| CN103664885A (en) | Preparation method of benzimidazole proton pump inhibitor intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140212 |